Toggle navigation EN

Publikationen 2009

  1. Doehring A, von Hentig N, Graff J, Salamat S, Schmidt M, Geisslinger G, Harder S, and Lötsch J. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dose requirements of methadone substitution. Pharmacogenet Genomics 2009 Jun;19(6):407-14
  2. Oertel BG, Kettner M, Scholich K, Renné C, Roskam B, Geisslinger G, Schmidt PH and Lötsch J. A common human µ-opioid receptor genetic variant diminishes the receptor signalling efficacy in brain regions processing the sensory information of pain. J Biol Chem 2009 Mar 6;284(10):6530-5
  3. Schiffmann S, Sandner J, Schmidt R, Birod K, Wobst I, Schmidt H, Angioni C, Geisslinger G, Grösch S. The selective COX-2-inhibitor celecoxib modulates sphingolipid synthesis. J Lipid Res 2009 Jan;50(1):32-40
  4. Gao W, Schmidtko A, Wobst I, Lu R, Angioni C, Geisslinger G. Prostaglandin D2 produced by hematopoietic prostaglandin D synthase contributes to LPS-induced fever. J Physiol Pharmacol 2009 Jun;60(2):145-50.
  5. Lötsch J, Flühr K, Neddermayer TJ, Doehring A, and Geisslinger G. The consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in pain. Clin Parmacol Ther 2009 Jan;85(1):25-30
  6. Flühr K, Neddermeyer TJ, Lötsch J. Capsaicin or menthol sensitization induces quantitative but no qualitative changes to thermal and mechanical pain thresholds. Clin J Pain 2009 Feb;25(2):128-31
  7. Mäurer C, Holland S, Pierre S, Potstada W, Scholich K. Sphingosine-1-phosphate induced mTOR-activation is mediated by the E3-ubiquitin ligase PAM. Cell Signal  2009, 21(2):293-300 
  8. Schmidtko A, Tegeder I, and Geisslinger G. No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci 2009 Jun;32(6):339-46
  9. Tegeder I and Lötsch J. Current evidence for a modulation of low back pain by human genetic variants. J Cell Mol Med 2009 Feb 17. [Epub ahead of print]
  10. S Pierre, T Eschenhagen, G Geisslinger, K Scholich. Capturing adenylyl cyclases as potential drug targets.Nature Reviews in Drug Discovery 2009 Apr;8(4):321-35
  11. Gao W, Schmidtko A, Lu R, Brenneis C, Angioni C, Schmidt R, and Geisslinger G. Prostaglandin D2 sustains the pyrogenic effect of prostaglandin E2. Eur J Pharmacol 2009 Apr 17;608(1-3):28-31
  12. Schiffmann S, Sandner J, Birod K, Wobst I, Angioni C, Ruckhäberle E, Kaufmann M, Ackermann H, Lötsch J, Schmidt H, Geisslinger G and Grösch S. Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 2009 May;30(5):745-52
  13. Lötsch J, von Hentig N, Freynhagen R, Griessinger N, Zimmermann M, Doehring A, Rohrbacher M, Sittl R, and Geisslinger G. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 2009 Jun;19(6):429-36
  14. Lötsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmöller J, and Geisslinger G. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 2009 Jul;144(1-2):119-24
  15. Harder S, Saal K, Blauth E, Beyer M, Gerlach FM. Appropriateness and surveillance of medication in a cohort of diabetic patients on polypharmacy. Int J Clin Pharm Ther 2009 Feb;47(2):104-10
  16. Grisk O, Steinbach AC, Ciecholewski S, Schlüter T, Klöting I, Schmidt H, Dazert E, Schaeffeler E, Steil L, Gauer S, Jedlitschky G, Schwab M, Geisslinger G, Hauser IA, Völker U, Kroemer HK, Rettig R. Multidrug resistance-related protein 2 genotype of the donor affects kidney graft function. Pharmacogenet Genomics 2009 Apr;19(4):276-288
  17. Doehring A, Freynhagen R, Griessinger N, Zimmermann M, Sittl R, von Hentig N, Geisslinger G, and Lötsch J. Cross-sectional assessment of consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain care. Clin J Pain 2009 November/December;25(9):781-785
  18. Geiger EV, Doehring A, Kirchhof A, and Lötsch J. Functional variants of the human 5-lipoxygenase gene and their genetic diagnosis. Prostaglandins, Leukotrienes & Essential Fatty Acids 2009 May-Jun;80(5-6):255-62
  19. Doehring A, Kirchhof A, and Lötsch J. Genetic diagnostics of functional variants of the human dopamine D2 receptor gene. Psychiatr Genet 2009 Oct;19(5):259-68
  20. Randriamboavonjy V, Badenhoop K, Schmidt H, Geisslinger G, Fisslthaler B, Fleming I. The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes. Basic Res Cardiol. 2009 May;104(3):333-40
  21. von Hentig N and Lötsch J. CYP3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in HIV-1 infected adults. Antimicrob Agents Chemother 2009 Aug;53(8):3524-7
  22. Ulbrich S, Schulke K, Groebner A, Reichenbach HD, Angioni C, Geisslinger G, Meyer H. Quantitative characterization of prostaglandins in the uterus of early pregnant cattle. Reproduction 2009 Aug;138(2):371-82
  23. Walter C, Felden L and Lötsch J. Bioequivalence criteria for transdermal fentanyl generics: Do these need a relook? Clin Pharmacokinet 2009 2009;48(10):625-33
  24. Lötsch J, Geisslinger G and Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacology & Therapeutics 2009 Nov;124(2):168-84
  25. Kuczka K, Baum K, Picard-Willems B, and Harder S. Long term administration of LMWH - pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients. Thrombosis Research 2009 Nov;124(5):625-30
  26. Walter C and Lötsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009 Dec;146(3):270-5
  27. Weigert A, Schiffmann S, Sekar D, Ley S, Menrad H, Werno C, Grösch S, Geisslinger G, and Brüne B. Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int J Cancer 2009 Nov 1;125(9):2114-21
  28. Maier TJ, Schiffmann S, Wobst I, Birod K, Angioni C, Hoffmann M, Lopez J L, Glaubitz C, Steinhilber D, Geisslinger G, and Grösch S. Cellular membrans funciton as storage compartment for celecoxib. J Mol Med 2009 Oct;87(10):981-93
  29. Altis K, Schmidtko A, Angioni C, Kuczka K, Schmidt H, Geisslinger G, Lötsch J, and Tegeder I. Analgesic efficacy of tramadol, pregabalin and ibuprofen in menthol-evoked cold hyperalgesia. Pain 2009 Dec 15;147(1-3):116-21
  30. Linke B, Pierre S, Coste O, Angioni C, Becker W, Maier T, Steinhilber D, Wittpoth C, Geisslinger G, and Scholich K. Toponomics analysis of drug-induced changes in arachidonic acid-dependent signaling pathways during spinal nociceptive processing. J Proteome Res 2009 Oct;8(10):4851-9
  31. Bockhart V, Constantin C, Häussler A, Pickert G, Popp L, Myrczek T, Sobotzik JM, Pasparakis M, Kuner R, Geisslinger G, Schultz C, Kress M, Tegeder I: Inhibitor kB kinase b deficiency in primary nociceptive neurons increases TRP channel sensitivity. J Neurosci 2009 Oct 14;29(41):12919-29
  32. Farnik H, El-Duweik J, Welsch C, Sarrazin C, Lötsch J, Zeuzem S, Geisslinger G, and Schmidt H. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS. J Chromatography B 2009 Dec 1;877(31):4001-6
  33. Tausch L, Henkel A, Siemoneit U, Poeckel D, Kather N, Franke L, Hofmann B, Schneider G, Angioni C, Geisslinger G, Skarke C, Holtmeier W, Beckhaus T, Karas M, Jauch J, Werz O. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense. J Immunol 2009 Sep 1;183(5):3433-42
  34. Zulauf L, Coste O, Marian C, Möser C, Brenneis C, and Niederberger E. Cofilin phosphorylation is involved in nitric oxide cGMP-mediated nociception. Biochem Biophys Res Commun 2009 Dec 25;390(4):1408-13